Extrait

EMERALD - RAD1901-308 - Elacestrant monotherapy vs. Standard of care for the treatment of patients with ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy: a phase 3 randomized open-label, active-controlled, multicenter trial

Liens

• e-cancer.fr
• Fiche de l'U.S. National Library of Medicine (NLM), sur ClinicalTrials.gov